Concerning cytokines releasing syndrome (CRS), in the previously reported trial of CAR-T cells targeting GPC-3, CRS occurred in 9/13 patients included one G5 CRS (toxic death on day 19) [60]. This evidence concerns the gene GPC3 and congenital rubella syndrome.